<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="111.00-Neurological-Childhood">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>111.00 Neurological - Childhood | Disability | SSA</title>
 
    <!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"true","rua.uprl":"false","rua.cprl":"true","rua.cprf":"false","rua.trans":"SJ-58bf15e4-70d6-4d49-bc49-6919f38410b4","rua.cook":"true","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"true","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n="true"=="true"?1:0,t="cookiepresent",a="im6jsaqx2s43i2inl3ba-f-7e580e7fa-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":22,"ak.ipv":4,"ak.proto":"h3","ak.rid":"13d7e1bf","ak.r":49961,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":62166,"ak.gh":"23.210.6.47","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762483906","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==HIdyKCzcmW5u4EZULbCqiRVDAXBT+4qKdBoamA0JAb40zxpy8H7V2oo1mDoAWyM5YEZhjkc/lOFCdbGrZ+jec3SNxO9qt0iGdXuC+uKwKm43cx4LwxwAQYuu15tj/HWB7IRKEdFpBiRfz8PCcElWpjeYjMSUuunpidWzx8ZoxS05fEdJnqUEiWqHxx2lo2DRBK5N1ilMf0fgz9eaOLNT/9dBKZRGcrAYCHY7i4r35bYNLRNfZ8zDdTsQYATsN38Tj1+uyu9yXV3Ycr+nwofXYjZTj4UFmqMQtT0HG91TU3dIIYv8H5jaAnsBIAwCwFULPZJjYNI8xNieeo+u2qr1t4UkQBtwKgh8sHnrx0GCunBtPr/e8fhcJT8UDdnSD2YsaWze3pyF7PAn5Hk7VSC2b9+vclYcfkiV6fH1I2DZp5o=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/111.00-Neurological-Childhood.htm#111_00"><meta property="og:title" content="111.00 Neurological - Childhood | Disability | SSA"><meta property="og:description" content="111.00-Neurological-Childhood"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0">Medical/Professional Relations</h2>
       </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="ChildhoodListings.htm">Listing of Impairments - Child Listings (Part B)</a></li> 
    <li aria-current="page">111.00 Neurological - Childhood</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

       <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        111.00 Neurological - Childhood<br>
        &nbsp;</b></span></h2>
        
                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>

	      <p align="left"><a href="#111_01" title=" 111.01 Category of Impairments, Neurological Disorders"><span><b>111.01</b><br>
Category of Impairments, Neurological Disorders </span></a><br>
<br>
<a href="#111_02" title=" 111.02 Epilepsy"><span><b>111.02</b><br>
Epilepsy</span></a><br>
<br>
<a href="#111_03" title=" 111.03 [Reserved]"><span><b>111.03</b><br>
[Reserved]</span></a><br>
              <br>
              <a href="#111_04" title=" 111.04 Vascular insult to the brain"><span><b>111.04</b><br>
Vascular insult to the brain</span></a><br>
              <br>
              <a href="#111_05" title=" 111.05 Benign brain tumors"><span><b>111.05</b><br>
Benign brain tumors</span></a><br>
<br>
<a href="#111_06" title=" 111.06 [Reserved]"> <span><b>111.06</b><br>
[Reserved]</span></a><br>
<br>
<a href="#111_07" title=" 111.07 Cerebral palsy"><span><b>111.07</b><br>
Cerebral Palsy</span></a><br>
<br>
<a href="#111_08" title="111.08 Spinal cord disorders"><span><b>111.08</b><br>
Spinal cord disorders</span></a><br>
<br>
<a href="#111_09" title=" 111.09 Communication impairment"> <span><b>111.09</b><br>
Communication impairment</span></a><br>
<br>
<a href="#111_10" title=" 111.10 [Reserved]"> <span><b>111.10</b><br>
[Reserved] </span></a><br>
<br>
<a href="#111_11" title=" 111.11 [Reserved]"> <span><b>111.11</b><br>
[Reserved] </span></a><br>
<br>
<a href="#111_12" title=" 111.12 Myasthenia gravis"> <span><b>111.12</b><br>
Myasthenia gravis </span></a><br>
<br>
<a href="#111_13" title=" 111.13 Muscular dystrophy"> <span><b>111.13</b><br>
Muscular dystrophy </span></a><br>
<br>
<a href="#111_14" title=" 111.14 Peripheral neuropathy"> <span><b>111.14</b><br>
Peripheral neuropathy </span></a><br>
<br>
<a href="#111_15" title=" 111.15 [Reserved]"> <span><b>111.15</b><br>
[Reserved] </span></a><br>
<br>
<a href="#111_16" title=" 111.16 [Reserved]"> <span><b>111.16</b><br>
[Reserved] </span></a><br>
<br>
<a href="#111_17" title=" 111.17 Neurodegenerative disorders of the central nervous system, such as Juvenile-onset Huntington�s disease and Friedreich�s ataxia"> <span><b>111.17</b><br>
Neurodegenerative disorders of the central nervous system, such as Juvenile-onset Huntington's disease and Friedreich's ataxia </span></a><br>
<br>
<a href="#111_18" title=" 111.18 Traumatic brain injury, characterized by disorganization of motor function in two extremities (see 111.00D1)"> <span><b>111.18</b><br>
Traumatic brain injury, characterized by disorganization of motor function in two extremities (see 111.00D1) </span></a><br>
<br>
<a href="#111_19" title=" 111.19 [Reserved]"> <span><b>111.19</b><br>
[Reserved] </span></a><br>
<br>
<a href="#111_20" title=" 111.20 Coma or persistent vegetative state, persisting for at least 1 month"> <span><b>111.20</b><br>
Coma or persistent vegetative state, persisting for at least 1 month </span></a><br>
<br>
<a href="#111_21" title=" 111.21 Multiple sclerosis"> <span><b>111.21</b><br>
Multiple sclerosis </span></a><br>
<br>
<a href="#111_22" title=" 111.22 Motor neuron disorders"> <span><b>111.22</b><br>
Motor neuron disorders </span></a><br>
<br>

                            </p></article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
   <p id="111_00"><u><b>111.00 Neurological</b></u></p>
   
      <p align="left" id="111_00A"> <br></p>
      <p>A. <em>Which neurological disorders do  we evaluate under these listings</em>? </p>
       <p>We evaluate epilepsy, coma or persistent vegetative state (PVS), and neurological disorders that cause disorganization of motor function, bulbar and neuromuscular dysfunction, 
        or communication impairment. Under this body system, we evaluate the limitations resulting from the impact of the neurological disease process itself. 
        If you have a neurological disorder(s) that affects your physical and mental functioning, we will evaluate your impairments under the rules we use to determine functional equivalence. 
        If your neurological disorder results in only mental impairment or  if you have a co-occurring mental condition that is not caused by your neurological disorder 
        (for example, Autism spectrum disorder), we will evaluate  your mental impairment under the mental disorders body system, 
        <a href="112.00-MentalDisorders-Childhood.htm#112_00" title="112.00 Mental Disorders - Childhood Page, Section 112.00" target="_blank">112.00</a>.</p>
          <p id="111_00B">B. <em>What evidence do we need to document your neurological disorder</em>?</p>
          <ol type="1">
              <li id="111_00B1">We need both medical and non-medical evidence (signs, symptoms,  and laboratory findings) to assess the effects of your neurological disorder.  Medical evidence should include your medical history, examination findings,  relevant laboratory tests, and the results of imaging. Imaging refers to  medical imaging techniques, such as x-ray, computerized tomography (CT),  magnetic resonance imaging (MRI), and electroencephalography (EEG). The imaging  must be consistent with the prevailing state of medical knowledge and clinical  practice as the proper technique to support the evaluation of the disorder. In  addition, the medical evidence may include descriptions of any prescribed  treatment and your response to it. We consider non-medical evidence such as  statements you or others make about your impairments, your restrictions, your  daily activities, or, if you are an adolescent, your efforts to work. </li>
              <li id="111_00B2">
                  We will make every  reasonable effort to obtain the results of your laboratory and imaging  evidence. When the results of any of these tests are part of the existing  evidence in your case record, we will evaluate the test results and all other  relevant evidence. We will not purchase imaging, or other diagnostic tests or  laboratory tests that are complex, may involve  significant risk, or that are invasive. We will not routinely purchase  tests that are expensive or not readily available.
              </li>
          </ol>
          <p id="111_00C">C. <em>How do we consider adherence to prescribed treatment in neurological disorders</em>? 
            In <a href="#111_02" title="Section 111.02">111.02</a> (Epilepsy) and <a href="#111_12" title="Section 111.12">111.12</a> (Myasthenia gravis),
    we require that limitations from these neurological disorders exist despite adherence to prescribed treatment.
    “Despite adherence to prescribed treatment” means that you have taken medication(s) or followed other treatment procedures for your neurological disorder(s)
    as prescribed by a physician for three consecutive months but your impairment continues to meet the other listing requirements despite this treatment.
    You may receive your treatment at a health care facility that you visit regularly, even if you do not see the same physician on each visit.
</p>
          <p id="111_00D">D. <em>What do we mean by disorganization of motor function</em>?<u> </u></p>
          <ol type="1">
              <li id="111_00D1">
                  Disorganization of motor function means interference, due to your neurological disorder, with movement of two extremities; 
                  i.e., the lower extremities, or upper extremities (including fingers, wrists, hands, arms, and shoulders). By two extremities we mean both lower extremities, 
                  or both upper extremities, or one upper extremity and one lower extremity. 
                  All listings in this body system, except for <a href="#111_02" title="Section 111.02">111.02</a> (Epilepsy) 
                  and <a href="#111_20" title="Section 111.20">111.20</a> (Coma and persistent vegetative state), 
                  include criteria for disorganization of motor function that results in an extreme limitation in your ability to:
</li>
              <ul>
                  <li>Stand up from a seated position; or</li>
                  <li>
                      <p>Balance while standing or walking; or </p>
                  </li>
                  <li>
                      <p>Use the upper extremities (e.g., fingers, wrists, hands, arms, and shoulders). </p>
                  </li>
              </ul>
              <li id="111_00D2">
                 Extreme limitation means the inability to stand up from a seated position, maintain balance in a standing  position and while walking, or use your upper extremities to independently  initiate, sustain, and complete age-appropriate activities. The assessment of  motor function depends on the degree of interference with standing up;  balancing while standing or walking; or using the upper extremities (including  fingers, hands, arms, and shoulders).
              </li>
              <ol type="a">
                  <li id="111_00D2a">
                      Inability to stand up from a seated position means that once seated you are unable to stand and maintain an upright  position without the assistance of another person or the use of an assistive  device, such as a walker, two crutches, or two canes.
                  </li>
                  <li id="111_00D2b">
                      Inability to maintain balance in a standing position means that you are unable to maintain an upright position  while standing or walking without the assistance of another person or an  assistive device, such as a walker, two crutches, or two canes.
                  </li>
                  <li id="111_00D2c">
                      Inability to use your upper extremities means that you have a loss of function of both upper extremities  (e.g., fingers, wrists, hands, arms, and shoulders) that very seriously limits  your ability to independently initiate, sustain, and complete age- appropriate  activities involving fine and gross motor movements. Inability to perform fine  and gross motor movements could include not being able to pinch, manipulate,  and use your fingers; or not being able to use your hands, arms, and shoulders  to perform gross motor movements, such as handling, gripping, grasping,  holding, turning, and reaching; or not being able to engage in exertional  movements such a lifting, carrying, pushing, and pulling.
                  </li>
              </ol>
              <li id="111_00D3">
                  For children who are not yet able to balance, stand up, or walk independently, we consider their function based  on assessments of limitations in the ability to perform comparable  age-appropriate activities with the lower and upper extremities, given normal  developmental milestones. For such children, an extreme level of limitation  means developmental milestones at less than one-half of the child's  chronological age.
              </li>
          </ol>
          <p id="111_00E">E. <em>What do we mean by bulbar and neuromuscular dysfunction</em>? 
    The bulbar region of the brain is responsible for controlling the bulbar muscles in  the throat, tongue, jaw, and face. 
    Bulbar and neuromuscular dysfunction refers to weakness in these muscles, resulting in breathing, swallowing, and speaking impairments. 
    Listings <a href="#111_12" title="Section 111.12">111.12</a> (Myasthenia gravis) and <a href="#111_22" title="Section 111.22">111.22</a> (Motor neuron  disorders) 
    include criteria for evaluating bulbar and neuromuscular dysfunction.  If your neurological disorder has resulted in a breathing disorder, we may evaluate that condition under the respiratory system, 
    <a href="103.00-Respiratory-Childhood.htm#103_00" target="_blank" title="103.00 Respiratory Disorders - Childhood Page, Section 103.00">103.00</a>.</p>
          <p id="111_00F">F. <em>What is epilepsy, and how do we evaluate it under <a href="#111_02" title="Section 111.02">111.02</a>?</em><u></u></p>
          <ol type="1">
              <li id="111_00F1">
                  Epilepsy is a pattern of recurrent and unprovoked seizures that are manifestations of abnormal electrical activity in the brain. 
                  There are various types of generalized and “focal” or partial seizures. In children, the most common potentially disabling seizure types are generalized tonic-clonic seizures, 
                  dyscognitive seizures (formerly complex partial  seizures), and absence seizures. 
                  However, psychogenic nonepileptic seizures and  pseudoseizures are not epileptic seizures for the purpose of <a href="#111_02" title="Section 111.02">111.02</a>.
    We evaluate psychogenic seizures and pseudoseizures under the mental disorders body system,
    <a href="112.00-MentalDisorders-Childhood.htm#112_00" title="112.00 Mental Disorders - Childhood Page, Section 112.00" target="_blank">112.00</a>.
</li>
              <ol type="a">
                  <li id="111_00F1a">Generalized tonic-clonic seizures are characterized by loss of consciousness accompanied by a tonic phase (sudden muscle tensing causing the child to lose postural control) followed by a clonic phase (rapid  cycles of muscle contraction and relaxation, also called convulsions). Tongue  biting and incontinence may occur during generalized tonic-clonic seizures, and  injuries may result from falling. </li>
                  <li id="111_00F1b">
                      Dyscognitive seizures are characterized by alteration of consciousness without convulsions or loss of muscle control. 
                      During the seizure, blank staring, change of facial expression, and automatisms (such as  lip smacking, chewing or swallowing, or repetitive simple actions, 
                      such as gestures or verbal utterances) may occur. During its course, a dyscognitive seizure may progress into a generalized tonic-clonic seizure 
                      (see <a href="#111_00F1a" title="Section 111.00 - Subsection F1a">111.00F1a</a>).
</li>
                  <li id="111_00F1c">
                      Absence seizures (petit mal) are also characterized by an alteration in consciousness, but are shorter than other generalized seizures (e.g., tonic-clonic and dyscognitive) seizures, generally lasting for only a  few seconds rather than minutes. They may present with blank staring, change of  facial expression, lack of awareness and responsiveness, and a sense of lost  time after the seizure. An aura never precedes absence seizures. Although  absence seizures are brief, frequent occurrence may limit functioning. This  type of seizure usually does not occur after adolescence.
                  </li>
                  <li id="111_00F1d">
                      Febrile seizures may occur in young children in association with febrile illnesses. We will consider seizures occurring during febrile illnesses. 
                      To meet <a href="#111_02" title="Section 111.02">111.02</a>,
    we require documentation of seizures during nonfebrile periods and epilepsy must be established.
</li>
              </ol>
              <li id="111_00F2">Description of seizure. We require at least one detailed description of your seizures from someone, preferably a medical  professional, who has observed at least one of your typical seizures. If you  experience more than one type of seizure, we require a description of each  type. </li>
              <li id="111_00F3">Serum drug levels. We do not require serum drug levels; therefore, we will not purchase them. However, if serum drug levels are  available in your medical records, we will evaluate them in the context of the  other evidence in your case record. </li>
              <li id="111_00F4">Counting seizures. 
              The period specified in <a href="#111_02A" title="Section 111.02 - Subsection A">111.02A</a> or <a href="#111_02B" title="Section 111.02 - Subsection B">B</a> cannot begin earlier than one month after you began prescribed treatment.
    The required number of seizures must occur within the period we are considering in connection with your application or continuing disability review.
    When we evaluate the frequency of your seizures,
    we also consider your adherence to prescribed treatment (see <a href="#111_00C" title="Section 111.00 - Subsection C">111.00C</a>).
    When we determine the number of seizures you have had in the specified period, we will:
</li>
              <ol type="a">
                  <li id="111_00F4a">Count multiple seizures occurring in a 24-hour period  as one seizure. </li>
                  <li id="111_00F4b">Count status epilepticus (a continuous series of  seizures without return to consciousness between seizures) as one seizure. </li>
                  <li id="111_00F4c">Count a dyscognitive seizure that progresses into a generalized tonic-clonic seizure as one generalized tonic-clonic seizure. </li>
                  <li id="111_00F4d">We do not count seizures that occur during a period when you are not adhering to prescribed treatment without good reason. 
                  When we determine that you had a good reason for not adhering to prescribed treatment, we will consider your physical, mental, educational, and communicative limitations 
                  (including any language barriers). We will consider you to have  good reason for not following prescribed treatment if, for example, 
                  the treatment is very risky for you due to its consequences or unusual nature, or if you are unable to afford prescribed treatment that you are willing to accept, 
                  but for which no free community resources are available. We will follow guidelines found in our policy, 
                  such as § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0930.htm#c" target="_blank" title="Code of Federal Regulations section 416.930 - Subsection c">416.930(c)</a> of this chapter,
    when we determine whether you have a good reason for not adhering to prescribed treatment.
</li>
                  <li id="111_00F4e">We do not count psychogenic nonepileptic seizures or pseudoseizures under <a href="#111_02" title="Section 111.02">111.02</a>.
    We evaluate these seizures under the mental disorders body system, <a href="112.00-MentalDisorders-Childhood.htm#112_00" title="112.00 Mental Disorders - Childhood Page, Section 112.00" target="_blank">112.00</a>.
</li>
              </ol>
              <li id="111_00F5">Electroencephalography (EEG) testing. We do not  require EEG test results; therefore, we will not purchase them. However, if EEG  test results are available in your medical records, we will evaluate them in  the context of the other evidence in your case record. </li>
          </ol>
          <p id="111_00G">G<em>. What is vascular insult to the brain, and how do we evaluate it under <a href="#111_04" title="Section 111.04">111.04</a>?</em></p>
          <ol type="1">
              <li id="111_00G1">Vascular insult to the brain (cerebrum, cerebellum, or  brainstem), commonly referred to as stroke or cerebrovascular accident (CVA), 
              is brain cell death caused by an interruption of blood flow within or leading to the brain, or by a hemorrhage from a ruptured blood vessel or aneurysm in the brain. 
              If you have a vision impairment resulting from your vascular insult, we may evaluate that impairment under the special senses body system, 
                  <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>.</li>
              <li id="111_00G2">We generally need evidence from at least 3 months after the vascular insult to determine whether you have disorganization of motor function under 
                  <a href="#111_04" title="Section 111.04">111.04</a>. In some cases, evidence of your vascular insult is sufficient to allow your claim within 3 months post-vascular insult. If we are unable to allow your claim within 3 months after your vascular insult, we will  defer adjudication of the claim until we obtain evidence of your neurological  disorder at least 3 months post-vascular insult. </li>
          </ol>
          <p id="111_00H">H.<em> What are benign brain tumors, and how do we evaluate them under <a href="#111_05" title="Section 111.05">111.05</a>?</em> 
    Benign brain tumors are noncancerous (nonmalignant) abnormal growths of tissue in or on the brain that invade healthy brain tissue or apply pressure on the brain or cranial nerves. 
    We evaluate their effects on your functioning as discussed in <a href="#111_00D" title="Section 111.00 - Subsection D">111.00D</a>.
    We evaluate malignant brain tumors under the cancer body system in <a href="113.00-NeoplasticDiseases-Malignant-Childhood.htm#113_00" target="_blank" title="113.00 Cancer-Childhood Page, Section 113.00">113.00</a>.
    If you have a vision impairment resulting from your benign brain tumor,
    we may evaluate that impairment under the special senses body system,
    <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>.
</p>
          <p id="111_00I">I. <em>What is cerebral palsy, and how do we evaluate it under <a href="#111_07" title="Section 111.07">111.07</a>?</em></p>
          <ol type="1">
              <li id="111_00I1">Cerebral palsy (CP) is a term that describes a group of static, nonprogressive disorders caused by abnormalities within the brain  that disrupt the brain's ability to control movement, muscle coordination, and  posture. The resulting motor deficits manifest very early in a child's  development, with delayed or abnormal progress in attaining developmental  milestones; deficits may become more obvious as the child grows and matures  over time.</li>
              <li id="111_00I2">We evaluate your signs and symptoms, such as ataxia, spasticity, flaccidity, athetosis, chorea, and difficulty with precise  movements when we determine your ability to stand up, balance, walk, or perform  fine and gross motor movements. We will also evaluate your signs, such as  dysarthria and apraxia of speech, and receptive and expressive language  problems when we determine your ability to communicate.</li>
              <li id="111_00I3">We will consider your other impairments or signs and symptoms that develop secondary to the disorder, such as post-impairment  syndrome (a combination of pain, fatigue, and weakness due to muscle  abnormalities); overuse syndromes (repetitive motion injuries); arthritis;  abnormalities of proprioception (perception of the movements and position of  the body); abnormalities of stereognosis (perception and identification of  objects by touch); learning problems; anxiety; and depression.</li>
          </ol>
          <p id="111_00J">J. <em>What are spinal cord disorders, and how do we evaluate them under <a href="#111_08" title="Section 111.08">111.08</a>?</em><u></u></p>
          <ol type="1">
              <li id="111_00J1">Spinal cord disorders may be congenital or caused by injury to the spinal cord. Motor signs and symptoms of spinal cord disorders  include paralysis, flaccidity, spasticity, and weakness.</li>
              <li id="111_00J2">Spinal cord disorders with complete loss of function 
              (<a href="#111_08A" title="Section 111.08 - Subsection A">111.08A</a>) addresses spinal cord disorders that result in complete lack of  motor, sensory, 
              and autonomic function of the affected part(s) of the body. </li>
              <li id="111_00J3">Spinal cord disorders with disorganization of motor function
              (<a href="#111_08B" title="Section 111.08 - Subsection B">111.08B</a>) addresses spinal cord disorders that result in less than complete loss of function of the affected part(s) of the body, 
              reducing,  but not eliminating, motor, sensory, and autonomic function. </li>
              <li id="111_00J4">When we evaluate your spinal cord disorder, we generally need evidence from at least 3 months after your symptoms began in  order to evaluate your disorganization of motor function. In some cases,  evidence of your spinal cord disorder may be  sufficient to allow your claim within 3 months after the spinal cord disorder.  If the medical evidence demonstrates total cord transection causing a loss of  motor and sensory functions below the level of injury, we will not wait 3  months but will make the allowance decision immediately.</li>
          </ol>
          <p id="111_00K">K. <em>What are communication impairments associated with neurological disorders, 
              and how do we evaluate them under <a href="#111_09" title="Section 111.09">111.09</a>? </em></p>
          <ol type="1">
              <li id="111_00K1">Communication impairments result from medically determinable neurological disorders that cause dysfunction in the parts of the 
              brain responsible for speech and language. Under <a href="#111_09A" title="Section 111.09">111.09</a>,
    we must have recent  comprehensive evaluation including all areas of affective and effective  communication, performed by a qualified professional, to document a  communication impairment associated with a neurological disorder.
</li>
              <li id="111_00K2">Under <a href="#111_09A" title="Section 111.09 - Subsection A">111.09A</a>,
    we need documentation from a qualified  professional that your neurological disorder has resulted in a speech deficit that  significantly affects your ability to communicate. Significantly affects means  that you demonstrate a serious limitation in communicating, and a person who is  unfamiliar with you cannot easily understand or interpret your speech.
</li>
              <li id="111_00K3">Under <a href="#111_09B" title="Section 111.09 - Subsection B">111.09B</a>,
    we need documentation from a qualified professional that shows that your neurological disorder has resulted in a  comprehension deficit that results in ineffective verbal communication for your age. 
              For the purposes of <a href="#111_09B" title="Section 111.09 - Subsection B">111.09B</a>, comprehension deficit means a deficit in  receptive language. Ineffective verbal communication means that you demonstrate  serious limitation in your ability to communicate orally on the same level as  other children of the same age and level of development.
</li>
              <li id="111_00K4">Under <a href="#111_09C" title="Section 111.09 - Subsection C">111.09C</a>,
    we need documentation of a neurological disorder that has resulted in hearing loss. Your hearing loss will be evaluated under listing 
              <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_10" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.10">102.10</a> 
              or <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_11" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.11">102.11</a>.
</li>
              <li id="111_00K5">We evaluate speech deficits due to non-neurological disorders under  <a href="2.00-SpecialSensesandSpeech-Adult.htm#2_09" target="_blank" title="2.00 Special Senses and Speech - Adult Page, Section 2.09">2.09</a>.</li>
          </ol>
          <p id="111_00L">L. <em>What are neurodegenerative disorders of the central nervous system, 
              such as Juvenile</em><em>-onset Huntington's disease and Friedreich's ataxia, 
              and how do we evaluate them under <a href="#111_17" title="Section 111.17">111.17</a>?</em> 
                Neurodegenerative disorders of the central nervous system are disorders characterized by progressive and irreversible degeneration of neurons or their supporting cells. 
                Over time, these disorders impair many of the body's motor or cognitive and other mental functions. 
                We consider neurodegenerative disorders of the central nervous system under 
                <a href="#111_17" title="Section 111.17">111.17</a> that we do not evaluate elsewhere in section <a href="#111_00" title="Section 111.00">111.00</a>, 
                such as juvenile-onset Huntington's disease (HD) and Friedreich's ataxia.  
                When these disorders result in solely cognitive and other mental functional limitations, we will evaluate the disorder under the  mental disorder listings, 
                <a href="112.00-MentalDisorders-Childhood.htm#112_00" target="_blank" title="112.00 Mental Disorders - Childhood Page, Section 112.00">112.00</a>.</p>
          <p id="111_00M">M. <em>What is traumatic brain injury, and how do we evaluate it under <a href="#111_18" title="Section 111.18">111.18</a>?</em><u></u></p>
          <ol type="1">
              <li id="111_00M1">Traumatic brain injury (TBI) is damage to the brain resulting from skull fracture, collision with an external force leading to a closed head injury, 
              or penetration by an object that enters the skull and makes contact with brain tissue. 
              We evaluate a TBI that results in coma or persistent vegetative state (PVS) under <a href="#111_20" title="Section 111.20">111.20</a>. </li>
              <li id="111_00M2">
                  We generally need evidence from at least 3 months after the TBI to evaluate whether you have disorganization of motor function under <a href="#111_18" title="Section 111.18">111.18</a>.
    In some cases, evidence of your TBI is sufficient to determine disability. If we are unable to allow your claim within 3 months post-TBI,
    we will defer adjudication of the claim until we obtain evidence of your neurological disorder at least 3 months post-TBI.
    If a finding of disability still is not possible at that time, we will again defer adjudication of the claim until we obtain evidence at least 6 months after your TBI.
</li>
          </ol>
          <p id="111_00N">N. <em>What are coma and persistent vegetative state, and how do we evaluate them under <a href="#111_20" title="Section 111.20">111.20</a>?</em> 
    Coma is a state of unconsciousness in which a child does not exhibit a sleep/wake cycle, and is unable to perceive or respond to external stimuli. Children  who do not fully emerge from coma may progress into persistent vegetative state  (PVS). PVS is a condition of partial arousal in which a child may have a low  level of consciousness but is still unable to react to external stimuli. In  contrast to coma, a child in a PVS retains sleep/wake cycles and may exhibit  some key lower brain functions, such as spontaneous movement, opening and  moving eyes, and grimacing. Coma or PVS may result from a TBI, a nontraumatic  insult to the brain (such as a vascular insult, infection, or brain tumor), or  a neurodegenerative or metabolic disorder. Medically induced comas should be  considered under the section pertaining to the underlying reason the coma was  medically induced and not under this section.</p>
          <p id="111_00O">O. <em>What is multiple sclerosis, and how do we evaluate it under <a href="#111_21" title="Section 111.21">111.21</a>?</em></p>
          <ol type="1">
              <li id="111_00O1">Multiple sclerosis (MS) is a chronic, inflammatory, degenerative disorder that damages the myelin sheath surrounding the nerve fibers in the brain and spinal cord. The damage disrupts the normal transmission  of nerve impulses within the brain and between the brain and other parts of the  body causing impairment in muscle coordination, strength, balance, sensation,  and vision. There are several forms of MS, ranging from slightly to highly  aggressive. Milder forms generally involve acute attacks (exacerbations) with  partial or complete recovery from signs and symptoms (remissions). Aggressive  forms generally exhibit a steady progression of signs and symptoms with few or  no remissions. The effects of all forms vary from child to child. </li>
              <li id="111_00O2">We evaluate your signs and symptoms, such as flaccidity, spasticity, spasms, incoordination, imbalance, tremor, physical fatigue, muscle weakness, 
              dizziness, tingling, and numbness when we determine  your ability to stand up, balance, walk, or perform fine and gross motor  movements, such as using your arms, hands, and fingers. 
              If you have a vision  impairment resulting from your MS, we may evaluate that impairment under the special senses body system, 
              <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>.</li>
          </ol>
          <p id="111_00P">P. <em>What are motor neuron disorders, and how do we evaluate them under <a href="#111_22" title="Section 111.22">111.22</a>?</em> 
    Motor neuron disorders are progressive neurological disorders that destroy the cells  that control voluntary muscle activity, such as walking, breathing, swallowing, and speaking. 
    The most common motor neuron disorders in children are progressive bulbar palsy and spinal muscular dystrophy syndromes. 
    We evaluate the effects of these disorders on motor functioning or bulbar and neuromuscular functioning.</p>
          <p id="111_00Q">Q. <em>How do we consider symptom</em><em>s</em><em> of fatigue in these listings?</em> 
    Fatigue is one of  the most common and limiting symptoms of some neurological disorders, such as  multiple sclerosis and myasthenia gravis. 
    These disorders may result in physical fatigue (lack of muscle strength) or mental fatigue (decreased awareness or  attention). When we evaluate your fatigue, we will consider the intensity, 
    persistence, and effects of fatigue on your functioning. This may include  information such as the clinical and laboratory data and other objective  evidence concerning your neurological deficit, 
    a description of fatigue  considered characteristic of your disorder, and information about your functioning. We consider the effects of physical fatigue on your ability to stand up, 
    balance, walk, or perform fine and gross motor movements using the criteria described in <a href="#111_00D" title="Section 111.00 - Subsection D">111.00D</a>. </p>
          <p id="111_00R">R. <em>How do we evaluate your neurological disorder when it does not meet one of these listings? </em></p>
          <ol type="1">
              <li id="111_00R1">If your neurological disorder does not meet the criteria of any of these listings, 
              we must also consider whether your impairment(s) meets the criteria of a listing in another body system. If  you have a severe medically determinable impairment(s) that does not meet a listing, 
              we will determine whether your impairment(s) medically equals a listing. 
              See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter. </li>
              <li id="111_00R2">If your impairment(s) does not meet or medically equal a listing, we will consider whether your impairment(s) functionally equals the  listings. 
              See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm#a" target="_blank" title="Code of Federal Regulations section 416.926 - Subsection a">416.926a</a> of this chapter. </li>
              <li id="111_00R3">We use the rules in § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm#a" target="_blank" title="Code of Federal Regulations section 416.994 - Subsection a">416.994a</a> of this chapter when we decide whether you continue to be disabled.</li>
          </ol>
          <p align="left" id="111_01">
              <b>
                  111.01
                  <strong>Category of Impairments, Neurological Disorders </strong>
              </b>
          </p>
          <p align="left" id="111_02"><b>111.02 <strong><u>Epilepsy</u></strong></b>,  documented by a detailed description of a typical seizure and characterized by  A or B:</p>
          <p id="111_02A">A. Generalized tonic-clonic seizures (see <a href="#111_00F1a" title="Section 111.00 - Subsection F1a">111.00F1a</a>),
    occurring at least once a month for at least 3 consecutive months
    (see <a href="#111_00F4" title="Section 111.00 - Subsection F4">111.00F4</a>) despite adherence to prescribed treatment
    (see <a href="#111_00C" title="Section 111.00 - Subsection C">111.00C</a>).
</p>
          <p>OR</p>
          <p id="111_02B">B.  Dyscognitive seizures (see <a href="#111_00F1b" title="Section 111.00 - Subsection F1b">111.00F1b</a>)
    or absence seizures (see <a href="#111_00F1c" title="Section 111.00 - Subsection F1c">111.00F1c</a>),
    occurring at least once a week for at least 3 consecutive months (see <a href="#111_00F4" title="Section 111.00 - Subsection F4">111.00F4</a>)
    despite adherence to prescribed treatment (see <a href="#111_00C" title="Section 111.00 - Subsection C">111.00C</a>).
</p>
          <p align="left" id="111_03"><b>111.03 </b>[Reserved]</p>
          <p align="left" id="111_04"><b>111.04 </b><strong><u>Vascular insult to the brain</u></strong>, 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>) in the ability to stand up from a seated position,
    balance while standing or walking, or use the upper extremities, persisting for at least 3 consecutive months after the insult.
</p>
          <p align="left" id="111_05"><b>111.05<i> </i></b><strong><u>Benign brain tumors</u></strong>, 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>) in the ability to stand up from a seated position,
    balance while standing or walking, or use the upper extremities.
</p>
          <p align="left" id="111_06"><b>111.06 </b>[Reserved]</p>
          <p align="left" id="111_07">
              <b>
                  111.07
              </b><strong><u>Cerebral palsy</u></strong>, characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>)
    in the ability to stand up from a seated position, balance while  standing or walking, or use the upper extremities.
</p>
          <p align="left" id="111_08">
              <b>
                  111.08
              </b><strong><u>Spinal cord disorders</u></strong>, characterized by A or B:
          </p>
          <p id="111_08A">A. Complete loss of function, 
    as described in <a href="#111_00J2" title="Section 111.00 - Subsection J2">111.00J2</a>,
    persisting for 3 consecutive months after the disorder (see <a href="#111_00J4" title="Section 111.00 - Subsection J4">111.00J4</a>).
</p>
          <p>OR</p>
          <p id="111_08B">B. Disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>) in the ability to stand up from a seated position,
    balance while standing or walking,
    or use the upper extremities persisting for 3 consecutive months after the disorder (see <a href="#111_00J4" title="Section 111.00 - Subsection J4">111.00J4</a>).
</p>
          <p align="left" id="111_09">
              <b>
                  111.09
              </b><strong>Communication  impairment</strong>, associated with documented neurological disorder and  one of the following:
          </p>
          <p id="111_09A">A. Documented speech deficit that significantly affects 
    (see <a href="#111_00K1" title="Section 111.00 - Subsection K1">111.00K1</a>) the clarity and content of the speech.</p>
          <p>OR </p>
          <p id="111_09B">B. Documented comprehension deficit resulting in ineffective verbal communication 
    (see <a href="#111_00K2" title="Section 111.00 - Subsection K2">111.00K2</a>) for age.</p>
          <p>OR </p>
          <p id="111_09C">C. Impairment of hearing as described under the criteria in 
             <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_10" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.10">102.10</a> 
            or <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_11" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.11">102.11</a>.</p>
          <p id="111_10"><b>111.10 </b>[Reserved]</p>
          <p id="111_11"><b>111.11 </b>[Reserved]</p>
          <p id="111_12"><b>111.12 </b><strong>Myasthenia  gravis</strong>, characterized by A or B despite adherence to prescribed treatment for at least 3 months 
            (see <a href="#111_00C" title="Section 111.00 - Subsection C">111.00C</a>): </p>
          <p id="111_12A">A. Disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
                resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>) in the ability to stand up from a seated position,
                balance while standing or walking, or use the upper extremities.
            </p>
          <p>OR</p>
          <p id="111_12B">B. Bulbar and neuromuscular dysfunction (see <a href="#111_00E" title="Section 111.00 - Subsection E">111.00E</a>), resulting in:</p>
          <ol type="1">
              <li id="111_12B1">One myasthenic crisis requiring mechanical ventilation; or</li>
              <li id="111_12B2">Need for supplemental enteral nutrition via a gastrostomy or parenteral nutrition via a central venous catheter.</li>
          </ol>
          <p id="111_13"><b>111.13 </b><strong>Muscular dystrophy</strong>, 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see  111.00D2) in the ability to stand up from a seated position, balance while  standing or walking, or use the upper extremities.
</p>
          <p id="111_14"><b>111.14 </b><strong>Peripheral neuropathy</strong>, 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>)
    in the ability to stand up from a seated position, balance while standing or  walking, or use the upper extremities.
</p>
          <p id="111_15"><b>111.15 </b>[Reserved]</p>
          <p id="111_16"><b>111.16 </b>[Reserved]</p>
          <p id="111_17"><b>111.17 </b><strong>Neurodegenerative disorders of the central nervous system, 
              such as Juvenile-onset Huntington's disease and Friedreich's ataxia</strong><u>,</u> 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>)
    in the ability to stand up from a seated position, balance while standing or walking, or use the  upper extremities.
</p>
          <p id="111_18"><b>111.18 </b><strong>Traumatic brain injury</strong>, 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>) in the ability to stand up from a seated position,
    balance while standing or walking, or use the upper extremities, persisting for at least 3 consecutive months after the injury.
</p>
          <p id="111_19"><b>111.19 </b>[Reserved]</p>
          <p id="111_20"><b>111.20 </b><strong>Coma or persistent vegetative state</strong><u>,</u> persisting for at least 1 month.</p>
          <p id="111_21"><b>111.21 </b><strong>Multiple sclerosis</strong>, 
    characterized by disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>)
    in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.
</p>
          <p id="111_22"><b>111.22 </b><strong>Motor neuron disorders</strong><u>,</u> characterized by A or B:</p>
          <p id="111_22A">A. Disorganization of motor function in two extremities (see <a href="#111_00D1" title="Section 111.00 - Subsection D1">111.00D1</a>),
    resulting in an extreme limitation (see <a href="#111_00D2" title="Section 111.00 - Subsection D2">111.00D2</a>)
    in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.
</p>
          <p>OR</p>
          <p id="111_22B">B. Bulbar and neuromuscular dysfunction (see <a href="#111_00E" title="Section 111.00 - Subsection E">111.00E</a>), resulting in:</p>
          <ol type="1">
              <li id="111_22B1">Acute respiratory failure requiring invasive mechanical ventilation; or</li>
              <li id="111_22B2">Need for supplemental enteral nutrition via a gastrostomy or parenteral nutrition via a central venous catheter.</li>
          </ol>
          
 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt on" href="#" title="Back to Top"></a>


</body></html>